Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sascha Fauser

Showing results (161-170 of 237) with videos related to

Pageof 24
Sort By:
Ophthalmology|February 6, 2018
Genome-Wide Association Study Reveals Variants in CFH and CFHR4 Associated with Systemic Complement Activation: Implications in Age-Related Macular DegenerationLaura Lorés-Motta, Constantin C Paun, Jordi Corominas, et al.
Clinical Ophthalmology (Auckland, N.Z.)|December 1, 2018
Clinical spectrum of severe chronic central serous chorioretinopathy and outcome of photodynamic therapyDanial Mohabati, Elon Hc van Dijk, Thomas J van Rijssen, et al.
Plos One|June 4, 2016
Analysis of Risk Alleles and Complement Activation Levels in Familial and Non-Familial Age-Related Macular DegenerationNicole T M Saksens, Yara T E Lechanteur, Sanne K Verbakel, et al.
Plos One|June 21, 2019
Metabolomics in serum of patients with non-advanced age-related macular degeneration reveals aberrations in the glutamine pathwayEveline Kersten, Sascha Dammeier, Soufiane Ajana, et al.
Pharmacogenetics and Genomics|October 2, 2015
A genetic variant in NRP1 is associated with worse response to ranibizumab treatment in neovascular age-related macular degenerationLaura Lorés-Motta, Freekje van Asten, Philipp S Muether, et al.
JAMA Ophthalmology|April 9, 2026
Interleukin 6 Inhibition With Vamikibart for Uveitic Macular Edema: The Phase 1 DOVETAIL Nonrandomized Clinical TrialSumit Sharma, Phoebe Lin, Allen Hu, et al.
Ophthalmic Epidemiology|August 27, 2014
Predicting non-response to ranibizumab in patients with neovascular age-related macular degenerationFreekje van Asten, Maroeska M Rovers, Yara T E Lechanteur, et al.
Translational Vision Science & Technology|September 4, 2020
Tear Proteomic Predictive Biomarker Model for Ocular Graft Versus Host Disease ClassificationOlivia E O'Leary, Andreas Schoetzau, Ludovic Amruthalingam, et al.
Translational Vision Science & Technology|June 24, 2024
Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal DiseasesBjörn Titz, Juliane Siebourg-Polster, Francois Bartolo, et al.
The British Journal of Ophthalmology|July 14, 2018
Discrepancy in current central serous chorioretinopathy classificationSumit Randhir Singh, Alexandre Matet, Elon H C van Dijk, et al.
Pageof 24

Showing results (161-170 of 237) with videos related to

Sort By:
Pageof 24
Ophthalmology|February 6, 2018
Genome-Wide Association Study Reveals Variants in CFH and CFHR4 Associated with Systemic Complement Activation: Implications in Age-Related Macular DegenerationLaura Lorés-Motta, Constantin C Paun, Jordi Corominas, et al.
Clinical Ophthalmology (Auckland, N.Z.)|December 1, 2018
Clinical spectrum of severe chronic central serous chorioretinopathy and outcome of photodynamic therapyDanial Mohabati, Elon Hc van Dijk, Thomas J van Rijssen, et al.
Plos One|June 4, 2016
Analysis of Risk Alleles and Complement Activation Levels in Familial and Non-Familial Age-Related Macular DegenerationNicole T M Saksens, Yara T E Lechanteur, Sanne K Verbakel, et al.
Plos One|June 21, 2019
Metabolomics in serum of patients with non-advanced age-related macular degeneration reveals aberrations in the glutamine pathwayEveline Kersten, Sascha Dammeier, Soufiane Ajana, et al.
Pharmacogenetics and Genomics|October 2, 2015
A genetic variant in NRP1 is associated with worse response to ranibizumab treatment in neovascular age-related macular degenerationLaura Lorés-Motta, Freekje van Asten, Philipp S Muether, et al.
JAMA Ophthalmology|April 9, 2026
Interleukin 6 Inhibition With Vamikibart for Uveitic Macular Edema: The Phase 1 DOVETAIL Nonrandomized Clinical TrialSumit Sharma, Phoebe Lin, Allen Hu, et al.
Ophthalmic Epidemiology|August 27, 2014
Predicting non-response to ranibizumab in patients with neovascular age-related macular degenerationFreekje van Asten, Maroeska M Rovers, Yara T E Lechanteur, et al.
Translational Vision Science & Technology|September 4, 2020
Tear Proteomic Predictive Biomarker Model for Ocular Graft Versus Host Disease ClassificationOlivia E O'Leary, Andreas Schoetzau, Ludovic Amruthalingam, et al.
Translational Vision Science & Technology|June 24, 2024
Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal DiseasesBjörn Titz, Juliane Siebourg-Polster, Francois Bartolo, et al.
The British Journal of Ophthalmology|July 14, 2018
Discrepancy in current central serous chorioretinopathy classificationSumit Randhir Singh, Alexandre Matet, Elon H C van Dijk, et al.
Pageof 24